Evidence map›Paper›PMID 41454768›Full record

ArticlePathologica2025

Harmonization trial of

Francesco Pepe, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Stefania Tommasi, Rosamaria Pinto, Dario De Biase, Thais Maloberti, Adele Busico, Alessandra Santoro and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Francesco PepeDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Gianluca RussoDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Claudia ScimoneDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Lucia PalumboDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Stefania TommasiMolecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Rosamaria PintoMolecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Dario De BiaseSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Thais MalobertiSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Adele BusicoDepartment of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Alessandra SantoroUOSD Laboratory of Oncohematology, Cellular Manipulation and Cytogenetics, Department of Genetic, Oncohematology a Rare Disease, AOR "Villa Sofia-Cervello", Palermo, Italy.
Domenico SalemiUOSD Laboratory of Oncohematology, Cellular Manipulation and Cytogenetics, Department of Genetic, Oncohematology a Rare Disease, AOR "Villa Sofia-Cervello", Palermo, Italy.
Elisa MelucciPathologic Anatomy and Histology Cytodiagnostics and Advanced Molecular Diagnostics, IRCCS Istituto Nazionale Tumori Regina Elena Roma.
Domenico CozzolinoDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Luisa ToffolattiCa' Foncello General Hospital, Surgical Pathology Unit, ULSS2 Marca Trevigiana, Treviso (TV).
Silvia BessiDepartmental Structure of Oncological Molecular Pathology, Oncological Department Azienda USL Toscana Centro, S. Stefano Hospital, Prato, Italy.
Claudia SarracinoDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Ilaria TomaiuoloDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Angelo MinucciDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Giuseppina RoscignoDepartment of Biology, Federico II University of Naples, Naples, Italy.
Francesco EspositoInstitute of Endotypes in Oncology, Metabolism and Immunology (IEOMI) "G. Salvatore", National Research Council (CNR), Naples, Italy.
Pierlorenzo PallanteInstitute of Endotypes in Oncology, Metabolism and Immunology (IEOMI) "G. Salvatore", National Research Council (CNR), Naples, Italy.
Sara LonardiOncology Unit 1, Department of Oncology Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Giancarlo PruneriDepartment of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Giancarlo TronconeDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Matteo FassanDepartment of Medicine - DIMED, University of Padua, Padua, Italy.
Umberto MalapelleDepartment of Public Health, Federico II University of Naples, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Molecular analysis of Methods: Each participating institution was requested to apply its own diagnostic testing strategy on 8 sections obtained from artificial reference specimens built to harbor Results: Overall, cell resuspension yielded higher amounts of DNA and RNA (SNU16 61.5 ng/µl, 38100.0 pg/µl; RT112 118.0/µl, 2140.0 pg/µl, respectively) in comparison with SNU16+ RT112 mixing cell block (0.7 ng/µl DNA and 412.0 pg/µl RNA). Moreover, FFPE samples showed a higher fragmentation index (DIN 1.2 and RIN not calculated) compared with cell line resuspension (DIN 2.2 and 9.5 for SNU16 and RT112; RIN 3.9 and 6.8 for SNU16 and RT112). All participating institutions identified Conclusions: NGS represents the most suitable approach in molecular profiling of

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3High-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceItalyMaleBiomarkers, TumorFGFR1 protein, humanFGFR2 protein, humanFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3cholangiocarcinomamolecular biomarker

Identifiers

PMID41454768
PMCPMC12743363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.